Ilyang Pharm confirms effect of treating Parkinson’s disease treatment from leukemia treatment ‘Supect’
‘Radotinib(product name: Supect),’ a leukemia treatment developed by Ilyang Pharmaceutical, showed a clinical trial result that it had an effect of treating ‘Parkinson’s disease’ as well.
Ilyang Pharm announced on the 26th that a research team at Johns Hopkins University conducted mechanism, cel...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
